{"id":36994,"date":"2025-07-09T13:20:15","date_gmt":"2025-07-09T05:20:15","guid":{"rendered":"https:\/\/flcube.com\/?p=36994"},"modified":"2025-07-09T13:20:16","modified_gmt":"2025-07-09T05:20:16","slug":"novartis-coartem-baby-approved-by-swissmedic-for-newborns-and-young-infants","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36994","title":{"rendered":"Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants"},"content":{"rendered":"\n

Swiss pharmaceutical giant Novartis (NYSE: NVS<\/a>) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.<\/p>\n\n\n\n

Addressing Unmet Medical Need<\/strong>
Previously, no antimalarial drugs were approved for infants weighing less than 4.5 kg. Healthcare providers had to adapt medications intended for older children, risking potential overdosing and toxicity. Additionally, existing malaria vaccines remain unapproved for neonatal use.<\/p>\n\n\n\n

Novel Formulation and Administration<\/strong>
Coartem Baby features a novel formulation specifically designed for infants, supported by MMV-funded research and developed as part of the PAMAfrica consortium. The consortium is backed by the European & Developing Countries Clinical Trials Partnership and the Swedish International Development Cooperation Agency. The drug is formulated to be dissolvable, even in breast milk, and includes a sweet cherry flavor to facilitate easier administration.<\/p>\n\n\n\n

Global Health Product Authorization and Accessibility<\/strong>
Eight African nations participated in the evaluation process for Coartem Baby. The treatment is expected to receive expedited approvals through Swissmedic’s global health product authorization pathway. Novartis plans to commercialize this pediatric treatment on a not-for-profit basis to enhance accessibility in malaria-endemic regions.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic…<\/p>\n","protected":false},"author":1,"featured_media":36995,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[140,865,15],"class_list":["post-36994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-novartis","tag-nyse-nvs","tag-product-approvals"],"yoast_head":"\nNovartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36994\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants\" \/>\n<meta property=\"og:description\" content=\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36994\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-09T05:20:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-09T05:20:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants\",\"datePublished\":\"2025-07-09T05:20:15+00:00\",\"dateModified\":\"2025-07-09T05:20:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994\"},\"wordCount\":233,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0904.webp\",\"keywords\":[\"Novartis\",\"NYSE: NVS\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36994#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36994\",\"name\":\"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0904.webp\",\"datePublished\":\"2025-07-09T05:20:15+00:00\",\"dateModified\":\"2025-07-09T05:20:16+00:00\",\"description\":\"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36994\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0904.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0904.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36994#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants - Insight, China's Pharmaceutical Industry","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36994","og_locale":"en_US","og_type":"article","og_title":"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants","og_description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.","og_url":"https:\/\/flcube.com\/?p=36994","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-09T05:20:15+00:00","article_modified_time":"2025-07-09T05:20:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36994#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36994"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants","datePublished":"2025-07-09T05:20:15+00:00","dateModified":"2025-07-09T05:20:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36994"},"wordCount":233,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp","keywords":["Novartis","NYSE: NVS","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36994#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36994","url":"https:\/\/flcube.com\/?p=36994","name":"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36994#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36994#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp","datePublished":"2025-07-09T05:20:15+00:00","dateModified":"2025-07-09T05:20:16+00:00","description":"Swiss pharmaceutical giant Novartis (NYSE: NVS) announced that it has received marketing approval from Swissmedic for its Coartem (artemether-lumefantrine) Baby, marking the first malaria medicine specifically indicated for newborns and young infants. Marketed as Riamet Baby in some countries, this breakthrough therapy was co-developed with Medicines for Malaria Venture (MMV) to address the critical treatment gap for this vulnerable patient population.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36994#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36994"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36994#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp","width":1080,"height":608,"caption":"Novartis' Coartem Baby Approved by Swissmedic for Newborns and Young Infants"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36994#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novartis’ Coartem Baby Approved by Swissmedic for Newborns and Young Infants"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0904.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36994"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36994\/revisions"}],"predecessor-version":[{"id":36997,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36994\/revisions\/36997"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36995"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}